910 Shares in Cencora, Inc. (NYSE:COR) Bought by Generali Investments CEE investicni spolecnost a.s.

Generali Investments CEE investicni spolecnost a.s. acquired a new position in shares of Cencora, Inc. (NYSE:COR) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 910 shares of the company’s stock, valued at approximately $253,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Net Worth Advisory Group grew its holdings in shares of Cencora by 1.4% in the 1st quarter. Net Worth Advisory Group now owns 2,645 shares of the company’s stock worth $736,000 after acquiring an additional 36 shares during the period. Whittier Trust Co. grew its holdings in Cencora by 0.6% in the fourth quarter. Whittier Trust Co. now owns 7,856 shares of the company’s stock valued at $1,765,000 after purchasing an additional 44 shares during the last quarter. Cullen Frost Bankers Inc. grew its holdings in Cencora by 1.1% in the fourth quarter. Cullen Frost Bankers Inc. now owns 4,463 shares of the company’s stock valued at $1,003,000 after purchasing an additional 47 shares during the last quarter. Private Trust Co. NA grew its holdings in Cencora by 2.5% in the first quarter. Private Trust Co. NA now owns 1,933 shares of the company’s stock valued at $538,000 after purchasing an additional 47 shares during the last quarter. Finally, Permanent Capital Management LP grew its holdings in Cencora by 4.0% in the first quarter. Permanent Capital Management LP now owns 1,238 shares of the company’s stock valued at $344,000 after purchasing an additional 48 shares during the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on COR shares. Robert W. Baird increased their price objective on shares of Cencora from $314.00 to $350.00 and gave the company an “outperform” rating in a research note on Thursday, May 8th. UBS Group increased their price target on shares of Cencora from $298.00 to $335.00 and gave the company a “buy” rating in a research report on Tuesday, April 29th. Wall Street Zen upgraded shares of Cencora from a “hold” rating to a “buy” rating in a research report on Wednesday, March 12th. Bank of America increased their target price on Cencora from $270.00 to $285.00 and gave the company a “neutral” rating in a report on Friday, April 11th. Finally, Wells Fargo & Company upgraded Cencora from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $274.00 to $337.00 in a report on Tuesday, June 3rd. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $306.33.

Insider Transactions at Cencora

In related news, CEO Robert P. Mauch sold 4,969 shares of the firm’s stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $289.33, for a total value of $1,437,680.77. Following the sale, the chief executive officer directly owned 47,582 shares of the company’s stock, valued at approximately $13,766,900.06. This trade represents a 9.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman Steven H. Collis sold 14,579 shares of the firm’s stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $292.62, for a total transaction of $4,266,106.98. Following the completion of the sale, the chairman directly owned 311,913 shares in the company, valued at $91,271,982.06. This represents a 4.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 34,127 shares of company stock worth $9,812,296. 10.80% of the stock is owned by corporate insiders.

Cencora Stock Up 1.7%

Shares of NYSE COR opened at $296.23 on Friday. Cencora, Inc. has a 1 year low of $218.65 and a 1 year high of $309.35. The firm’s 50 day moving average price is $291.12 and its 200 day moving average price is $267.51. The firm has a market cap of $57.42 billion, a P/E ratio of 34.37, a price-to-earnings-growth ratio of 1.47 and a beta of 0.57. The company has a debt-to-equity ratio of 6.01, a quick ratio of 0.52 and a current ratio of 0.87.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.07 by $0.35. Cencora had a return on equity of 344.71% and a net margin of 0.55%. The business had revenue of $75.50 billion for the quarter, compared to analysts’ expectations of $75.41 billion. During the same quarter last year, the firm earned $3.80 earnings per share. The business’s revenue was up 10.3% on a year-over-year basis. As a group, sell-side analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, June 2nd. Shareholders of record on Friday, May 16th were paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.74%. The ex-dividend date of this dividend was Friday, May 16th. Cencora’s payout ratio is 25.52%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.